C-Q4XZSensei Biotherapeutics
oncology, PAM pathway inhibition, oral multi-node therapy
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-Q4XZ
C-Q4XZC-Q4XZoncology, PAM pathway inhibition, oral multi-node therapy
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Sensei Biotherapeutics states that it is pioneering first-in-class precision cancer immunotherapies targeting ASPH, which it describes as a uniquely human, tumor-specific antigen expressed across more than 20 cancer types and associated with poor survival. The company presents the view that immunologically optimized therapies, including cancer vaccines and T-cell therapies, together with companion diagnostics and its SPIRIT platform, can drive robust target-specific immune responses and improve outcomes for patients with unmet needs.
SourceSensei Biotherapeutics states that cancer can be treated by therapeutics that teach the immune system to recognize and attack cancer. The company says effective immunotherapy depends on detecting subtle differences in antigen expression between cancer cells and normal 'self' tissue, and that its SPIRIT platform is designed to overcome the disabled immune recognition caused by cancer while supporting a precision-medicine approach with companion diagnostics.
SourceSensei Biotherapeutics states that it aims to push the boundaries of science and imagination to discover and develop innovative medicines for patients, focusing on immunotherapies for cancer and infectious disease. The company presents itself as driven by rigorous science, innovative treatments, and data-driven decision making, with a belief that its work can alter the treatment landscape and create value for patients and society.
SourceSensei Biotherapeutics presents itself as a clinical-stage biotechnology company focused on developing first-in-class immune-activating biologic therapies for cancers with unmet need, with the belief that innovative science, precision medicine, and therapies that engage both innate and adaptive immunity can improve treatment outcomes, identify the patients most likely to benefit, and change the treatment landscape for patients and society.
Source